Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 77.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,180 shares of the pharmaceutical company’s stock after acquiring an additional 2,257 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $2,413,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Aveo Capital Partners LLC lifted its stake in shares of Vertex Pharmaceuticals by 77.3% in the fourth quarter. Aveo Capital Partners LLC now owns 1,076 shares of the pharmaceutical company’s stock valued at $438,000 after purchasing an additional 469 shares during the period. Gryphon Financial Partners LLC lifted its position in shares of Vertex Pharmaceuticals by 26.5% during the 4th quarter. Gryphon Financial Partners LLC now owns 1,978 shares of the pharmaceutical company’s stock valued at $805,000 after acquiring an additional 414 shares during the period. Brown Advisory Inc. lifted its position in shares of Vertex Pharmaceuticals by 25.0% during the 4th quarter. Brown Advisory Inc. now owns 3,522 shares of the pharmaceutical company’s stock valued at $1,433,000 after acquiring an additional 705 shares during the period. Trexquant Investment LP boosted its stake in shares of Vertex Pharmaceuticals by 161.2% during the 4th quarter. Trexquant Investment LP now owns 3,968 shares of the pharmaceutical company’s stock worth $1,615,000 after acquiring an additional 2,449 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VRTX shares. Barclays downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $472.00 to $509.00 in a research note on Monday, August 5th. Morgan Stanley upped their price target on shares of Vertex Pharmaceuticals from $402.00 to $455.00 and gave the company an “equal weight” rating in a report on Thursday, July 11th. Piper Sandler lifted their price objective on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Redburn Atlantic started coverage on Vertex Pharmaceuticals in a research note on Thursday, June 27th. They issued a “buy” rating and a $545.00 target price on the stock. Finally, Argus boosted their price target on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the stock a “buy” rating in a report on Monday, June 17th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $486.36.

Insider Activity

In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now directly owns 9,994 shares in the company, valued at approximately $4,987,006. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares in the company, valued at $4,987,006. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total value of $1,075,521.60. Following the transaction, the chief marketing officer now owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The disclosure for this sale can be found here. In the last three months, insiders sold 34,047 shares of company stock valued at $16,843,806. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ:VRTX opened at $464.92 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $341.85 and a 12-month high of $510.64. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. The firm has a market cap of $119.97 billion, a PE ratio of 30.17 and a beta of 0.40. The company has a fifty day simple moving average of $482.66 and a 200 day simple moving average of $452.12.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the previous year, the business posted $3.53 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.